



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BOYLE, et al.

Serial No.: 09/613,591

Group Art Unit No.: 1647

Filed: JULY 10, 2000

Examiner: R. Debern

For: COMBINATION THERAPY FOR CONDITIONS
LEADING TO BONE LOSS

Docket No.: A-379CIP5

RECEIVED

AUG 10 2001

TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY AND AMENDMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:

This is in response to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated July 24, 2001.

AMENDMENT

Please substitute the initial sequence listing with the attached amended sequence.

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

Timothy J. Gaul
Attorney for Applicant
Registration No.: 33,111
Phone: (805) 447-2688
Date: August 6, 2001

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

August 6, 2001
DateChristina A. Gutierrez
Signature